Takeda is looking for new approaches and technologies that can help them address challenges/opportunities in gastroenterology, oncology, neuroscience and rare genetic & hematology.
Xinterra pioneered the combined use of high throughput experimentation and artificial intelligence applied to materials, seeking efficient approaches to overcome slowness, high costs and overall limitation to innovation imposed by traditional materials R&D processes. Buonassisi will discuss Xinterra's combined use of high throughput experimentation and artificial intelligence applied to materals.
A Complete Cybersecurity Solution for Smart Cities Andrew Surwilo CEO & Co-Founder, Cytex
Cytex is a leading innovator in AI-driven full spectrum cybersecurity platform designed to protect organizations' data and assets. The patented Cytex Unified Resilience Platform provides network security, cloud security, application security, and compliance management, in a single solution. Notably, the Cytex Audify Compliance Verification Platform enables real-time, continuous compliance monitoring across various regulatory frameworks eliminating the reliance on traditional unreliable point-in-time assessments. Additionally, Cytex demonstrates a strong commitment to cybersecurity education by providing free phishing simulation software to businesses, non-profits, and municipalities, aiming to enhance organizational resilience against cyber threats.
P&G is looking for new approaches and technologies that can help them to address key business challenges/opportunities.
We are seeking start-ups or researchers focused on new sensing approaches relevant to industrial/manufacturing processes to participate in the Anglo American FutureSmart MiningTM Sensing Open Forum taking place virtually from June 9th - 17th 2021.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
P&G is seeking innovative chemistry to help us reduce impact in the use phase (superior performance in cold water) and/ or ingredients with positive/ neutral carbon footprint impact.
Catherine Havasi, CEO, Luminoso